>Marché européen des médicaments contre le pinguéculumPar traitement (larmes artificielles/ lubrifiants topiques , gouttes ophtalmiques stéroïdiennes, gouttes anti-inflammatoires non stéroïdiennes et autres), type de formulation (gouttes ophtalmiques, pommades ophtalmiques et autres), mode d'achat (sur ordonnance, en vente libre (OTC)), type de médicament (de marque et génériques), type de population (gériatrique et adultes), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (pharmacies hospitalières, pharmacies de détail, pharmacies en ligne et autres) - Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et perspectives du marché européen des médicaments contre le pinguéculum
Le pinguéculum est une excroissance conjonctivale typique qui n'est pas maligne. Les facteurs de risque de progression du pinguécula comprennent l'exposition aux rayons ultraviolets, les traumatismes, le vent, la poussière et le sable, le travail en extérieur pendant une longue durée et l'âge avancé.
Le rapport sur le marché européen des médicaments contre le pinguéculum fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et localisé, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste. Notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Data Bridge Market Research analyse que le marché européen des médicaments contre le pinguéculum connaîtra une croissance de 5,9 % au cours de la période de prévision de 2022 à 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (Customisale jusqu'en 2014-2019) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, prix en USD |
|
Segments couverts |
Par traitement (larmes artificielles/lubrifiants topiques, gouttes ophtalmiques stéroïdiennes, gouttes anti-inflammatoires non stéroïdiennes et autres), type de formulation (gouttes ophtalmiques, pommades ophtalmiques et autres), mode d'achat (sur ordonnance, en vente libre (OTC)), type de médicament (de marque et génériques), type de population (gériatrie et adultes), utilisateur final (hôpitaux, cliniques spécialisées, soins à domicile et autres), canal de distribution (pharmacies hospitalières, pharmacies de détail, pharmacies en ligne et autres) |
|
Pays couverts |
Russie, Espagne, Turquie, Allemagne, Italie, Royaume-Uni, France, Hongrie, Autriche, Suisse, Pays-Bas, Pologne, Irlande, Norvège, Lituanie et reste de l'Europe |
|
Acteurs du marché couverts |
AbbVie Inc., Akorn Operating Company LLC, Alcon Inc., Amneal Pharmaceuticals LLC, Bausch & Lomb Incorporated, Bayer AG, Johnson & Johnson Consumer Inc., Novartis AG, OASIS Medical, Inc., SAGER PHARMA, Santen Pharmaceutical Co., Johnson & Johnson Vision Care, Inc., Similasan Corporation, Sylentis, Laboratoires Théa, Wellona Pharma et Zydus Group, entre autres |
Définition du marché
A pingueculum is a typical conjunctival growth that is not malignant. This is the transparent, delicate tissue that encircles the eye's white region (sclera). Pinguecula word is derived from the Latin word pinguis, which means "fat" or "grease." The growth occurs in the part of the conjunctiva that is exposed when the eye is open. The risk factors for the progression of pinguecula include exposure to ultraviolet light, trauma, wind, dust and sand, working outdoors for a long duration and advancing age. Individuals having a history of elevated UV exposure and those living closer to the equator have a higher incidence (outdoor work). According to certain research, males have a somewhat higher incidence than females, which could simply be due to a higher rate of UV exposure. It appears as a tiny, yellowish bump on the conjunctiva close to the cornea. It may emerge on either side of the cornea.
Europe Pingueculum Drugs Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below
- Rising prevalence of pinguecula disorders and ocular pains
In 2020, according to the published article "Prevalence and associated factors of pinguecula in Western Turkey" by ULAKBİM Journal Systems, the study included 1443 individuals over the age of 20 years of Western Turkey, where it was found that 52.5% of people had pinguecula and out of that 52.5%, the prevalence of pinguecula was higher in males (58.4%), as compared to females (46.8%).
The prevalence of pinguecula disease keeps showing a surge in growth as several environmental and external factors worldwide. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface. Thus, the rising prevalence of pinguecula disorder and ocular pain is expected to drive the Europe pingueculum drugs market in the forecast period.
- Rise in chronic UV radiation exposure due to ozone defect
In 2019, according to the published journal by "the Association for Research in Vision and Ophthalmology," it was stated that early pinguecula was found to have a prevalence of 39.5% in the temporal conjunctiva and 43.9% in the nasal conjunctiva respectively. That the reported amount of time spent on outdoor activities was 19.6% and 16.1% for less than 2 hours, 44.7% and 52.2% for 4 to 6 hours, respectively and 75.0% in both fields for more than 6 hours, indicates a positive correlation between the prevalence of pinguecula and the amount of time spent on outdoor activities and UV radiation exposure.
There is a correlation between increased exposure to UV and a higher prevalence of pinguecula. This demonstrates that there is a connection between the prevalence of pinguecula and exposure to sunlight. The ozone layer defect is also leading to an increase in the exposure of UV exposure which is increasing the prevalence of pinguecula disorder. Thus, it is expected to drive The Europe pingueculum drugs market growth.
- Initiatives and plans to lessen the prevalence of eye illnesses
In 2020, The VISION 2020: The Right to Sight initiative was introduced in 1999 by the World Health Organization (WHO), Geneva, Switzerland and the International Agency for the Prevention of Blindness (IAPB), London, England. The Europe initiative VISION2020 seeks to end avoidable blindness by 2020 and focuses on the main causes of avoidable visual impairment.
According to the article by CDC (Centres for disease control and prevention), in 2022, through Vision Health Initiative (VHI) and diverse stakeholders, CDC initiated a coordinated national public health framework to prevent blindness and vision impairment.
The initiatives and plans are working as an opportunity for the market. Hence, initiatives and plans to lessen the prevalence of eye illness are expected to act as an opportunity for the growth of the Europe pingueculum drugs market.
Restraints/Challenges
- Adverse effects of steroid eye drops
Ophthalmologists or optometrists are recommended by patients with mild to severe pinguecula for a thorough examination and prompt treatment. Most often, local tropical steroids, tropical immune modulators, lubricating ointment, gel, or drops are used to treat them.
Prednisolone is the topical steroid that is most frequently used to treat ocular pain. The prednisolone acetate ophthalmic suspension has below mentioned common adverse effects:
- Eyes sting, burn, or itch for one to two minutes after using this medicine
- Vision temporarily obscured
- Increased light sensitivity
- Visual alterations
- Experiencing a foreign object in your eyes
- Allergic responses
Lack of healthcare facilities for eye treatment
As per IntechOpen 2020 report, the prevalence of blindness and ocular disorders in high-income countries is 0.3 per 1000 people, but in low-income countries, the estimation is 1.5 per 1000. This shows the unmet need for ophthalmology care in low-income countries
Another major problem in low-income countries is the lack of awareness regarding ocular pain and other disorders. Many research studies report the high requirement of low-income countries for eye health care and their unmet needs are still gaining attention among many healthcare organizations. Hence, the poor healthcare facility for eye treatments in low and middle-income countries may act as restraints for the growth of the Europe pingueculum drugs market.
Post-COVID-19 Impact on the Europe Pingueculum Drugs Market
La COVID-19 a eu un impact négatif sur le marché. Les confinements et l’isolement pendant la pandémie compliquent la gestion de la maladie et l’observance du traitement. Le manque d’accès aux établissements de santé pour le traitement de routine et l’administration des médicaments aura un impact supplémentaire sur le marché.
Développement récent
- En mai 2022, Alcon a annoncé l'acquisition du collyre pharmaceutique EYSUVIS (suspension d'étabonate de lotéprednol) de Kala Pharmaceuticals, Inc. L'acquisition viendra compléter la gamme de gouttes ophtalmiques Systane de la société, qui comprend notamment des formulations sans conservateur.
- En septembre 2022, Johnson & Johnson Vision Care, Inc. a annoncé le lancement de sa nouvelle innovation, les lentilles de contact Acuvue Oasys Max–day et ses lentilles de contact multifocales pour la presbytie. De plus, ces nouvelles lentilles de contact sont dotées de la nouvelle technologie pour répondre au style de vie numérique intense
Portée du marché européen des médicaments contre le pinguéculum
Le marché européen des médicaments contre le pinguéculum est classé en sept segments notables en fonction du type de médicament, du traitement, de la formulation, du mode d'achat, du type de population, de l'utilisateur final et du canal de distribution. La croissance parmi ces segments vous aidera à analyser les segments de croissance maigres dans les industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour les aider à prendre des décisions stratégiques pour identifier les principales applications du marché.
Traitement
- Larmes artificielles/Lubrifiants topiques
- Collyre stéroïde
- Collyre non stéroïdien
- Autres
En fonction du traitement, le marché européen des médicaments contre le pinguéculum est segmenté en larmes artificielles/lubrifiants topiques, gouttes ophtalmiques stéroïdiennes, gouttes ophtalmiques non stéroïdiennes et autres.
Type de formulation
- Gouttes pour les yeux
- Pommades pour les yeux
- Autres
Sur la base de la formulation, le marché européen des médicaments contre le pinguéculum est segmenté en gouttes ophtalmiques, pommades ophtalmiques et autres.
Mode d'achat
- Ordonnance
- En vente libre (OTC)
En fonction du mode d'achat, le marché européen des médicaments contre le pinguéculum est segmenté en médicaments sur ordonnance et en vente libre (OTC).
Type de médicament
- De marque
- Génériques
En fonction du type de population, le marché européen des médicaments contre le pinguéculum est segmenté en médicaments de marque et génériques.
Type de population
- Gériatrie
- Adultes
En fonction du type de population, le marché européen des médicaments contre le pinguéculum est segmenté en gériatrique et adulte.
Utilisateur final
- Hôpitaux
- Cliniques spécialisées
- Soins à domicile
- Autres
En fonction de l’utilisateur final, le marché européen des médicaments contre le pinguéculum est segmenté en hôpitaux, cliniques spécialisées, soins à domicile et autres.
Canal de distribution
- Pharmacies de détail
- Pharmacies hospitalières
- Pharmacies en ligne
- Autres
En fonction du canal de distribution, le marché européen des médicaments contre le pinguéculum est segmenté en pharmacies de détail, pharmacies hospitalières, pharmacies en ligne et autres.
Analyse/perspectives régionales du marché des médicaments contre le pinguéculum
Le marché européen des médicaments contre le pinguéculum est analysé et des informations sur la taille du marché et les tendances sont fournies par pays, type de médicament, traitement, formulation, mode d'achat, type de population, utilisateur final et canal de distribution comme référencé ci-dessus.
Les pays couverts par le rapport sur le marché européen des médicaments contre le pinguéculum sont la Russie, l'Espagne, la Turquie, l'Allemagne, l'Italie, le Royaume-Uni, la France, la Hongrie, l'Autriche, la Suisse, les Pays-Bas, la Pologne, l'Irlande, la Norvège, la Lituanie et le reste de l'Europe.
L'Espagne devrait dominer le marché européen des médicaments contre le pinguéculum en raison des initiatives et des plans visant à réduire la prévalence de cette maladie oculaire. Le marché européen des médicaments contre le pinguéculum devrait croître en raison de la prévalence croissante du pinguéculum dans les zones tropicales et de la croissance de la population gériatrique.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données, tels que les ventes de produits neufs et de remplacement, la démographie des pays et les tarifs d'importation et d'exportation, sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la forte concurrence des marques locales et nationales et l'impact des canaux de vente sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des médicaments contre le Pingueculum
Le paysage concurrentiel du marché européen des médicaments contre le pinguéculum fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence européenne, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination de l'application. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées au marché européen des médicaments contre le pinguéculum.
Certains des principaux acteurs opérant sur le marché européen des médicaments contre le pinguéculum sont AbbVie Inc., Akorn Operating Company LLC, Alcon Inc., Amneal Pharmaceuticals LLC, Bausch & Lomb Incorporated, Bayer AG, Johnson & Johnson Consumer Inc., Novartis AG, OASIS Medical, Inc., SAGER PHARMA, Santen Pharmaceutical Co., Johnson & Johnson Vision Care, Inc., Similasan Corporation, Sylentis, Laboratoires Théa, Wellona Pharma et Zydus Group, entre autres.
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des parts de marché des entreprises, les normes de mesure, l'Europe par rapport aux régions et l'analyse des parts des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.
Personnalisation disponible
Data Bridge Market Research est un leader dans la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, le marché des produits remis à neuf et une analyse de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE PINGUECULUM DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE PINGUECULUM DRUGS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 TREATMENT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END-USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDERMIOLOGY
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES
4.4 PIPELINE ANALYSIS FOR THE EUROPE PINGUECULUM DRUGS MARKET
4.5 INDUSTRIAL INSIGHTS:
4.6 CONCLUSION:
5 EUROPE PINGUECULUM DRUGS MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF PINGUECELA DISORDERS AND OCULAR PAINS
6.1.2 RISE IN THE CHRONIC UV RADIATION EXPOSURE DUE TO OZONE DEFECT
6.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES
6.1.4 RISING OPHTHALMIC EMERGENCIES IN THE GERIATRIC PATIENT
6.2 RESTRAINTS
6.2.1 STRINGENT RULES & REGULATIONS
6.2.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT
6.3 OPPORTUNITIES
6.3.1 INITIATIVES AND PLANS TO LESSEN THE PREVALENCE OF EYE ILLNESSES
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
6.3.3 INCREASE IN HEALTHCARE SPENDING AND ACCESSIBLE INCOME
6.4 CHALLENGES
6.4.1 ADVERSE EFFECTS OF STEROID EYE DROPS
6.4.2 LACK OF SKILLED OPHTHALMOLOGISTS
7 EUROPE PINGUECULUM DRUGS MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS
7.2.1 DEMULCENT
7.2.2 EMOLLIENTS
7.3 STEROID EYE DROPS
7.3.1 KETONE STEROIDS
7.3.1.1 PREDNISOLONE
7.3.1.2 DEXAMETHASONE
7.3.1.3 FLUROMETHOLONE
7.3.1.4 MEDRYSONE
7.3.1.5 RIMEXOLONE
7.3.1.6 OTHERS
7.3.2 ESTER STEROID (LOTERPREDNOL)
7.4 NON-STEROIDAL ANTI-INFLAMMATORY DROPS
7.5 OTHERS
8 EUROPE PINGUECULUM DRUGS MARKET, BY FORMULATION
8.1 OVERVIEW
8.2 EYE DROPS
8.2.1 EYE DROPS WITH PRESERVATIVES
8.2.2 PRESERVATIVE-FREE EYE DROPS
8.3 EYE OINTMENTS
8.3.1 WITH PRESERVATIVES
8.3.2 PRESERVATIVE-FREE
8.3.3 OTHERS
8.4 OTHERS
9 EUROPE PINGUECULUM DRUGS MARKET, MODE OF PURCHASE
9.1 OVERVIEW
9.2 PRESCRIPTION
9.3 OVER THE COUNTER (OTC)
10 EUROPE PINGUECULUM DRUGS MARKET, BY DRUGS TYPE
10.1 OVERVIEW
10.2 BRANDED
10.3 GENERICS
11 EUROPE PINGUECULUM DRUGS MARKET, BY POPULATION TYPE
11.1 OVERVIEW
11.2 GERIATRIC
11.2.1 MALE
11.2.2 FEMALE
11.3 ADULTS
11.3.1 MALE
11.3.2 FEMALE
12 EUROPE PINGUECULUM DRUGS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 SPECIALTY CLINICS
12.4 HOME HEALTHCARE
12.5 OTHERS
13 EUROPE PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 RETAIL PHARMACIES
13.3 HOSPITAL PHARMACIES
13.4 ONLINE PHARMACIES
13.5 OTHERS
14 EUROPE PINGUECULUM DRUGS MARKET, BY REGION
14.1 EUROPE
14.1.1 SPAIN
14.1.2 RUSSIA
14.1.3 TURKEY
14.1.4 GERMANY
14.1.5 ITALY
14.1.6 U.K.
14.1.7 FRANCE
14.1.8 HUNGARY
14.1.9 AUSTRIA
14.1.10 SWITZERLAND
14.1.11 NETHERLANDS
14.1.12 POLAND
14.1.13 IRELAND
14.1.14 NORWAY
14.1.15 LITHUANIA
14.1.16 REST OF EUROPE
15 EUROPE PINGUECULUM DRUGS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ALCON INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 ABBVIE INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 BAUSCH & LOMB INCORPORATED
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 BAYER AG
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 JOHNSON & JOHNSON VISION CARE, INC.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 AKORN OPERATING COMPANY LLC
17.6.1 COMPANY SNAPSHOT
17.6.2 . PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 AMNEAL PHARMACEUTICALS LLC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 EYERIS VISIONCARE PVT. LTD.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 LABORATOIRES THÉA
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 MAYA BIOTECH PRIVATE LIMITED
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENTS
17.11 NOVARTIS AG
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 OASIS MEDICAL, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 PRESTIGE CONSUMER HEALTHCARE, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 SAGER PHARMA
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 SANTEN PHARMACEUTICAL CO., LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 SIMILASAN CORPORATION
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 SPECTRA VISION CARE
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENTS
17.18 SYLENTIS
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENTS
17.19 WELLONA PHARMA
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 ZYDUS GROUP
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 2 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DROPS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE EYE DROPS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE PRESCRIPTION IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE OVER THE COUNTER (OTC) IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 19 EUROPE BRANDED IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE GENERICS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 22 EUROPE GERIATRIC IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 24 EUROPE ADULTS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 26 EUROPE PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 27 EUROPE HOSPITALS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE SPECIALTY CLINICS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE HOME HEALTHCARE IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 EUROPE RETAIL PHARMACIES IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE HOSPITAL PHARMACIES IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE ONLINE PHARMACIES IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE PINGUECULUM DRUGS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 37 EUROPE PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 38 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 EUROPE STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 EUROPE KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 EUROPE PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 42 EUROPE EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 44 EUROPE PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 45 EUROPE PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 46 EUROPE PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 47 EUROPE GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 48 EUROPE ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 49 EUROPE PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 50 EUROPE PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 51 SPAIN PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 52 SPAIN ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 SPAIN STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 SPAIN KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SPAIN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 56 SPAIN EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 57 SPAIN EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 SPAIN PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 59 SPAIN PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 60 SPAIN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 61 SPAIN GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 62 SPAIN ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 63 SPAIN PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 SPAIN PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 RUSSIA PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 66 RUSSIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 RUSSIA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 RUSSIA KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 RUSSIA PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 70 RUSSIA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 71 RUSSIA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 72 RUSSIA PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 73 RUSSIA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 74 RUSSIA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 75 RUSSIA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 76 RUSSIA ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 77 RUSSIA PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 78 RUSSIA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 79 TURKEY PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 80 TURKEY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 TURKEY STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 TURKEY KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 TURKEY PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 84 TURKEY EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 85 TURKEY EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 86 TURKEY PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 87 TURKEY PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 88 TURKEY PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 89 TURKEY GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 90 TURKEY ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 91 TURKEY PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 92 TURKEY PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 93 GERMANY PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 94 GERMANY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 GERMANY STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 GERMANY KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 GERMANY PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 98 GERMANY EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 99 GERMANY EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 100 GERMANY PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 101 GERMANY PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 102 GERMANY PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 103 GERMANY GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 104 GERMANY ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 105 GERMANY PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 106 GERMANY PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 107 ITALY PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 108 ITALY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 ITALY STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 ITALY KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 ITALY PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 112 ITALY EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 113 ITALY EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 114 ITALY PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 115 ITALY PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 116 ITALY PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 117 ITALY GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 118 ITALY ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 119 ITALY PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 120 ITALY PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 121 U.K. PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 122 U.K. ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 U.K. STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 U.K. KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 U.K. PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 126 U.K. EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 127 U.K. EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 128 U.K. PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 129 U.K. PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 130 U.K. PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 131 U.K. GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 132 U.K. ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 133 U.K. PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 134 U.K. PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 FRANCE PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 136 FRANCE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 FRANCE STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 FRANCE KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 FRANCE PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 140 FRANCE EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 141 FRANCE EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 142 FRANCE PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 143 FRANCE PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 144 FRANCE PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 145 FRANCE GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 146 FRANCE ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 147 FRANCE PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 148 FRANCE PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 149 HUNGARY PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 150 HUNGARY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 HUNGARY STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 HUNGARY KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 HUNGARY PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 154 HUNGARY EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 155 HUNGARY EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 156 HUNGARY PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 157 HUNGARY PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 158 HUNGARY PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 159 HUNGARY GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 160 HUNGARY ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 161 HUNGARY PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 162 HUNGARY PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 163 AUSTRIA PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 164 AUSTRIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 AUSTRIA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 AUSTRIA KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 AUSTRIA PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 168 AUSTRIA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 169 AUSTRIA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 170 AUSTRIA PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 171 AUSTRIA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 172 AUSTRIA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 173 AUSTRIA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 174 AUSTRIA ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 175 AUSTRIA PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 176 AUSTRIA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 177 SWITZERLAND PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 178 SWITZERLAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 SWITZERLAND STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 SWITZERLAND KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 SWITZERLAND PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 182 SWITZERLAND EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 183 SWITZERLAND EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 184 SWITZERLAND PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 185 SWITZERLAND PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 186 SWITZERLAND PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 187 SWITZERLAND GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 188 SWITZERLAND ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 189 SWITZERLAND PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 190 SWITZERLAND PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 191 NETHERLANDS PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 192 NETHERLANDS ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 NETHERLANDS STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 NETHERLANDS KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 NETHERLANDS PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 196 NETHERLANDS EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 197 NETHERLANDS EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 198 NETHERLANDS PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 199 NETHERLANDS PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 200 NETHERLANDS PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 201 NETHERLANDS GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 202 NETHERLANDS ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 203 NETHERLANDS PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 204 NETHERLANDS PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 205 POLAND PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 206 POLAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 POLAND STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 POLAND KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 POLAND PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 210 POLAND EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 211 POLAND EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 212 POLAND PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 213 POLAND PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 214 POLAND PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 215 POLAND GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 216 POLAND ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 217 POLAND PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 218 POLAND PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 219 IRELAND PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 220 IRELAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 IRELAND STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 IRELAND KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 IRELAND PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 224 IRELAND EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 225 IRELAND EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 226 IRELAND PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 227 IRELAND PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 228 IRELAND PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 229 IRELAND GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 230 IRELAND ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 231 IRELAND PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 232 IRELAND PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 233 NORWAY PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 234 NORWAY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 235 NORWAY STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 NORWAY KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 NORWAY PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 238 NORWAY EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 239 NORWAY EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 240 NORWAY PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 241 NORWAY PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 242 NORWAY PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 243 NORWAY GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 244 NORWAY ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 245 NORWAY PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 246 NORWAY PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 247 LITHUANIA PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 248 LITHUANIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 249 LITHUANIA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 250 LITHUANIA KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 251 LITHUANIA PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 252 LITHUANIA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 253 LITHUANIA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 254 LITHUANIA PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 255 LITHUANIA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 256 LITHUANIA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 257 LITHUANIA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 258 LITHUANIA ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 259 LITHUANIA PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 260 LITHUANIA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 261 REST OF EUROPE PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE PINGUECULUM DRUGS MARKET: SEGMENTATION
FIGURE 2 EUROPE PINGUECULUM DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PINGUECULUM DRUGS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PINGUECULUM DRUGS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE PINGUECULUM DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PINGUECULUM DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PINGUECULUM DRUGS MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE PINGUECULUM DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE PINGUECULUM DRUGS MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE PINGUECULUM DRUGS MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS AND THE RISE IN THE GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE EUROPE PINGUECULUM DRUGS MARKET GROWTH FROM 2022 TO 2029
FIGURE 12 ARTIFICIAL TEARS/TOPICAL LUBRICANTS SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE PINGUECULUM DRUGS MARKET FROM 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PINGUECULUM DRUGS MARKET
FIGURE 14 EUROPE PINGUECULUM DRUGS MARKET: BY TREATMENT, 2021
FIGURE 15 EUROPE PINGUECULUM DRUGS MARKET: BY TREATMENT, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE PINGUECULUM DRUGS MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 17 EUROPE PINGUECULUM DRUGS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 EUROPE PINGUECULUM DRUGS MARKET: BY FORMULATION, 2021
FIGURE 19 EUROPE PINGUECULUM DRUGS MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE PINGUECULUM DRUGS MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 21 EUROPE PINGUECULUM DRUGS MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 22 EUROPE PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, 2021
FIGURE 23 EUROPE PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
FIGURE 24 EUROPE PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)
FIGURE 25 EUROPE PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 26 EUROPE PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, 2021
FIGURE 27 EUROPE PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, CAGR (2022-2029)
FIGURE 29 EUROPE PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 30 EUROPE PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, 2021
FIGURE 31 EUROPE PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)
FIGURE 32 EUROPE PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 33 EUROPE PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 34 EUROPE PINGUECULUM DRUGS MARKET: BY END USER, 2021
FIGURE 35 EUROPE PINGUECULUM DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 36 EUROPE PINGUECULUM DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 EUROPE PINGUECULUM DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 39 EUROPE PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 40 EUROPE PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 41 EUROPE PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 EUROPE PINGUECULUM DRUGS MARKET: SNAPSHOT (2021)
FIGURE 43 EUROPE PINGUECULUM DRUGS MARKET: BY COUNTRY (2021)
FIGURE 44 EUROPE PINGUECULUM DRUGS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 EUROPE PINGUECULUM DRUGS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 EUROPE PINGUECULUM DRUGS MARKET: BY TREATMENT (2022-2029)
FIGURE 47 EUROPE PINGUECULUM DRUGS MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
